Obicetrapib has received its first regulatory approval worldwide, with the European Commission authorizing two cholesterol medicines, NewAmsterdam Pharma and Menarini announced on September 21.
Both treatments target elevated low-density lipoprotein cholesterol, or LDL-C. Ubeslo contains 10 mg of obicetrapib. Evlarco combines that dose with 10 mg of ezetimibe. The authorizations cover primary hypercholesterolaemia, including heterozygous familial and non-familial forms, and mixed dyslipidaemia. Obicetrapib is an oral medicine, not a statin.
The decision rests on late-stage clinical testing in the BROADWAY, BROOKLYN and TANDEM studies. The companies report LDL-cholesterol reductions of up to 40% for obicetrapib alone and approximately 50% for the combination, both compared with placebo, with comparable tolerability.
Those findings establish cholesterol lowering, not a demonstrated reduction in heart attacks or other cardiovascular events. PREVAIL, an ongoing Phase 3 trial involving more than 9,500 participants, is examining that separate question. A favorable laboratory measurement and a better clinical outcome are not interchangeable claims.
Menarini holds European commercialization rights. The next step is turning clinical progress into patient access, a different task from securing authorization. The announcement does not establish country-by-country availability or prices.